BeiGene (BeOne Medicines Ltd.) announced that its Board compensation committee approved the issuance of 42,648 restricted share units (RSUs) on 1 June 2026 under the Fourth Amended and Restated 2016 Share Option and Incentive Plan.

The new award covers 381 employees and corresponds to 554,424 ordinary shares, representing approximately 0.04% of the company’s issued share capital on the grant date. Each RSU relates to one American Depositary Share (ADS), with every ADS equal to 13 ordinary shares.

Based on the closing price of US$279.68 per ADS on the grant date, the total notional value of the grant is about US$11.93 million (approximately HK$93.60 million).

Vesting Terms • 25% of the RSUs vest on each anniversary of the last trading day of the month following the employee’s start date over four years, subject to continued employment. • For 195 non-senior-manager grantees, 25% vests annually on 29 May from 2026 to 2029, also contingent on continued employment. • Certain awards may vest earlier in the event of termination or a change of control.

There are no performance conditions or claw-back provisions attached to these awards. The compensation committee considers the structure market-competitive and consistent with the plan’s objectives.

Following this grant, 61.08 million ordinary shares remain available for future awards under the 2016 Share Option and Incentive Plan.